Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 5/20 | 0.64 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 2/20 | 0.56 |
| ▸ | NMBR | P28336 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29867952 | 0.97 | GHSR (0.62) | GHSRACE | |
| SCHEMBL31593292 | 0.93 | GHSR (0.57) | GHSRSLC15A2ACENMBR | |
| SCHEMBL31593361 | 0.93 | ACE (0.59) | GHSRACE | |
| SCHEMBL29590552 | 0.91 | GHSR (0.58) | GHSRSLC15A2 | |
| SCHEMBL31593250 | 0.91 | GHSR (0.58) | GHSRNMBR | |
| SCHEMBL29866466 | 0.90 | GHSR (0.67) | GHSR | |
| SCHEMBL31593305 | 0.90 | GHSR (0.61) | GHSRACE | |
| SCHEMBL31468802 | 0.90 | GHSR (0.61) | GHSRACE | |
| SCHEMBL31593388 | 0.90 | GHSR (0.61) | GHSRACE | |
| SCHEMBL31468788 | 0.90 | GHSR (0.61) | GHSRACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | GHSR 2961/4885SLC15A2 291/4885ACE 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.